Evidence map›Paper›PMID 36170773›Full record

Observational studyMultiple sclerosis and related disorders2022

Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.

Lingyao Kong, Xiaofei Wang, Hongxi Chen, Ziyan Shi, Yanlin Lang, Ying Zhang, Hongyu Zhou

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lingyao KongDepartment of Neurology, West China Hospital, Sichuan University. No.37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, China.
Xiaofei WangDepartment of Neurology, West China Hospital, Sichuan University. No.37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, China.
Hongxi ChenDepartment of Neurology, West China Hospital, Sichuan University. No.37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, China.
Ziyan ShiDepartment of Neurology, West China Hospital, Sichuan University. No.37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, China.
Yanlin LangDepartment of Neurology, West China Hospital, Sichuan University. No.37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, China.
Ying ZhangDepartment of Neurology, West China Hospital, Sichuan University. No.37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, China.
Hongyu ZhouDepartment of Neurology, West China Hospital, Sichuan University. No.37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, China. Electronic address: zhouhy@scu.edu.cn.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic outbreak raises the question of whether immunization is recommended for patients with CNS demyelinating diseases. On the one hand, existing studies suggested that SARS-CoV-2 vaccinations are not associated with increased risk of relapse activity. On the other hand, case reports with acute CNS demyelinating disease post vaccination were emerging and raising clinicians' attention.

methodsIn this longitudinal observational study, we included 556 patients with neuromyelitis optica spectrum disorder (NMOSD) and 280 patients with relapsing-remitting multiple sclerosis (RRMS). Each vaccinated patient was matched to two unvaccinated patients according to age, gender, ARR and immunotherapy status, based on propensity score matching model (PSM). The primary outcome is the short- and medium-term risk of relapse, which were evaluated by Kaplan-Meier analysis between groups.

resultsIn our cohort, 649 patients (77.6%) have not yet been vaccinated, mainly due to their concerns about relapse. After PSM, 109 vaccinated patients with NMOSD, 218 PS-matched unvaccinated patients with NMOSD, 78 vaccinated patients with RRMS, and 156 PS-matched unvaccinated patients with RRMS were included in the survival analysis to explore the safety of vaccines, with a median of 9-month follow-up. Following the first vaccination dose, 10 patients with NMOSD (9.2%) and four with RRMS (5.1%) experienced an acute relapse. Meanwhile, in the PS-matched unvaccinated group, 15 patients with NMOSD (6.9%) and 12 patients with RRMS (7.7%) presented with an acute relapse. There was no significant difference between the two curves in both NMOSD and RRMS groups over the course of the observation period. There were no significant differences in demographic characteristics, clinical characteristics, and symptoms of relapses between the vaccinated and PS-matched unvaccinated groups. Post vaccination adverse events (ADE) were reported in 39 individuals (20.9%).

conclusionOur results indicate that inactivated SARS-CoV-2 vaccines appear safe for patients with CNS demyelinating diseases.

Indexed as

COVID-19COVID-19 VaccinesMultiple SclerosisNeuromyelitis OpticaHumansPandemicsRecurrenceSARS-CoV-2VaccinationCOVID-19 VaccinesDemyelinationMultiple sclerosisNeuromyelitis optica spectrum disordersRemissionSARS-CoV-2 vaccination

Identifiers

PMID36170773
PMCPMC9472679
OpenAlexW4295708789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.